Dynavax Technologies Corp., of Berkeley, Calif., said results of a prospective analysis of the diabetic subset population from its Phase III trial (HBV-16) showed the superiority of Heplisav vs. Engerix-B (GlaxoSmithKline plc) at all measured time points.